Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells

NUTTAVUT SUMRANSUB1*, NIPHAT JIRAPONGWATTANA1*, PRANISA JAMJUNTRA1, SUYANEE THONGCHOT1, THAWEESAK CHIEOCHANSIN2,3, PA-THAI YENCHITSOMANUS2,3, PETI THUWAJIT1, MALEE WARNNISSORN4, PORNCHAI O-CHAROENRAT5 and CHANITRA THUWAJIT1

Departments of 1Immunology and 2Research and Development, 3Siriraj Center of Research Excellence for Cancer Immunotherapy (siCORE-CIT); Departments of 4Pathology and 5Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Received March 27, 2019; Accepted December 12, 2019

DOI: 10.3892/ol.2020.11338

Correspondence to: Dr Chanitra Thuwajit, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Street, Bangkok 10700, Thailand
E-mail: cthuwajit@yahoo.com

*Contributed equally

Key words: breast cancer, cancer stem cell, dendritic cell, T lymphocytes, programmed death ligand 1

Abstract. Cancer stem cells (CSCs) underpin the resistance of breast cancer (BC) cells to therapy. Dendritic cell (DC)-based treatment is efficacious and safe, but the efficiency of this technique for targeting CSCs in BC treatment requires further investigation. The present study aimed to investigate the ability of DCs pulsed with breast CSC antigens to activate effector lymphocytes for killing BC cells. CD44+/CD24- CSCs were isolated from BCA55-121, an in-house patient-derived BC cell line, and acquisition of stemness properties was confirmed by upregulated expression of OCT4A and a superior proliferative capacity in colony formation assays compared with whole population of BCA55-121 (BCA55-121-WP). DCs were differentiated from monocytes from peripheral blood of healthy donors and pulsed with CSC total RNA. Maturation of the CSC RNA-pulsed DCs was confirmed by increased expression of CD11c, CD40, CD83, CD86 and HLA-DR, as well as reduced CD14 expression compared with monocytes. Total lymphocytes co-cultured with CSC RNA-pulsed DCs were analyzed by flow cytometry for markers including CD3, CD4, CD8, CD16 and CD56. The results revealed that the co-cultures contained mostly cytotoxic CD8+ T lymphocytes followed by CD4+ T lymphocytes and smaller populations of natural killer (NK) and NKT cells. ELISA was used to measure IFN-γ production, and it was revealed that activated CD4+ and CD8+ lymphocytes produced more IFN-γ compared with naïve T cells, suggesting that CD8+ T cells were effector T cells. CSC RNA was a more efficient antigen source compared with RNA from mixed BC cells for activating tumor antigen-specific killing by T cells. These CSC-specific effector T cells significantly induced BC cell apoptosis at a 20:1 effector T cell:tumor cell ratio. Of note, the breast CSCs cultures demonstrated resistance to effector T cell killing, which was in part due to increased expression of programmed death ligand 1 in the CSC population. The present study highlights the potential use of CSC RNA for priming DCs in modulating an anticancer immune response against BC.

Introduction

Breast cancer (BC) is the most common cancer in women worldwide with an estimated 2.4 million cases in 2015 (1). Standard treatments of patients with BC include loco-regional therapy (surgery and radiation), hormonal therapy, chemotherapy and molecular targeted therapy. The afore-mentioned treatment regimens have existed for a number of years, however, drug resistance and cancer recurrence still pose a problem for the treatment of patients with BC (2,3). A subpopulation of cells in tumors exhibit stem cell properties, including dormancy, self-renewal, infinite proliferation and multi-lineage differentiation (4,5). Studies in various types of cancer, in particular BC, have demonstrated that cancer stem cells (CSCs) subpopulations play a role in cancer recurrence, therapy resistance, metastasis and aggressive relapse (6-8). Therefore, CSCs are becoming important targets for cancer therapy (8,9). In a number of studies investigating BC, distinct cell subpopulations with high tumorigenicity and stem cell properties have been isolated (10,11). A tumorigenic subpopulation of BC cells that express CD44 with low or negative CD24 expression (CD44+CD24low) has been identified as a major breast CSC population (12).

Dendritic cell (DC)-based treatment has been widely studied over the past two decades (13-15). Most of the clinical trials of DC-based treatment in melanoma, prostate cancer, malignant glioma and renal cell carcinoma demonstrated an increase in median overall survival with minimal toxicity (16). In a previous study, human breast CSCs were injected into NOD/SCID mouse mammary fat pads and used to prime human DCs; after mature DCs were re-injected into mice,
they exhibited longer survival times and lower tumor masses compared with mice that had not received DC treatment (17). These studies suggested that tumor antigen-activated DCs may be a promising therapy for BC and that CSC antigens may be used for the production of efficacious DC-based treatment in treating refractory human cancers in general.

To the best of our knowledge, no study has evaluated DC-based therapy using human breast CSC antigens to activate effector T cells for cancer cell killing to date. Thus, the aim of this study was to explore whether CSC antigens may evoke an effective immune response against both CSC and non-CSC cells, which may cause tumor regression and prevent tumor resistance.

Materials and methods

Isolation and characterization of primary BC cell culture. The study protocol was evaluated and approved by the Siriraj Institutional Review Board (approval nos. Si520/2010 and Si321/2016; Bangkok, Thailand). Written informed consent was obtained from all individual participants prior to enrollment in the study between January 2010 and December 2018. A fresh luminal BC tissue sample (4x10^4 cells/ml), in this mixture, which was incubated at 37˚C for 1 h at baseline and at the end of the experiment. The data obtained from CSCs are presented compared with the whole population of cultured BC cells.

Western blotting of CSC-related proteins and programmed death ligand-1 (PD-L1). Proteins (20 µg) extracted from BCA55-121 cells using extraction buffer (0.25 M Tris-HCl pH 6.8, 5% glycerol, 4% SDS, 10% β-mercaptoethanol, 0.001% (w/v) bromophenol blue) were separated using 12% polyacrylamide gels (Sigma-Aldrich; Merck KGaA). Proteins (20 µg) extracted from BCA55-121 cells using extraction buffer were then transferred to 0.45-µm nitrocellulose membranes. The membranes were blocked with 5% BSA in TBST at room temperature and incubated overnight at 4˚C with anti-human OCT4A rabbit monoclonal antibody (1:1,000; cat. no. 2840; Cell Signaling Technology, Inc.), anti-human OCT4A rabbit monoclonal antibody (1:1,000; cat. no. 2840; Cell Signaling Technology, Inc.), anti-human homeobox protein Nanog (NANOG) rabbit monoclonal antibody (1:1,000; cat. no. 4903, Cell Signaling Technology, Inc.) or anti-human PD-L1 rabbit monoclonal antibody (1:500; cat. no. ab205921; Abcam). The membranes were then washed three times with TBST and incubated with a HRP-conjugated goat anti-rabbit IgG antibody (1:1,000; cat. no. ab6721; Abcam) for 2 h at room temperature. The proteins were visualized using SuperSignal West Pico Chemi-luminescent Substrate (Thermo Fisher Scientific, Inc.) under a Gel Documentation System (G:Box; version EF; Syngene). Anti-β-actin antibody (1:5,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-7778) was incubated for 1 h at room temperature to detect β-actin as a loading control.

Soft agar colony formation assay. A 0.5% base agar layer was prepared by mixing 1% agarose with 2X DMEM (or DMEM/F12) supplemented with 20% FBS in a 1:1 ratio. An over-layer of 0.35% agar cell suspension was prepared by mixing 0.7% agarose with 2X DMEM (or DMEM/F12) in a ratio of 1:1. BCA55-121 cells and their CSCs were suspended (4x10^4 cells/ml), in this mixture, which was incubated at 37˚C in 5% CO₂ for 14-21 days. Subsequently, cells were fixed with 5% glutaraldehyde and stained with 0.5% crystal violet at room temperature for 15 and 30 min, respectively. Colonies with a diameter >500 µm were counted and surface areas of the formed colonies were measured using an inverted microscope IX71 (original magnification, x100) at 1 h (baseline) and at the end of the experiment. The data obtained from CSCs are presented compared with the whole population of cultured BC cells.
Dendritic cell activation and immunophenotyping assay. Venous blood (50 ml) from three healthy donors with aged between 25 and 30 years with no underlying diseases was collected in 0.1% heparin solution and peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep® lymphocyte separation media (Biowest) according to the manufacturer's instructions. Briefly, heparinized blood was overlaid on Lymphoprep® media and centrifuged at 400 x g at 20°C for 30 min. PBMCs were collected and washed three times at room temperature using 200 x g centrifugations for 10 min with PBS or RBC lysis buffer (150 mM NH₄Cl, 10 mM NaHCO₃, and 1.26 mM EDTA), and then resuspended in AIM-V™ medium (Thermo Fisher Scientific, Inc.) and plated onto 6-well plates at 5x10⁶ cells/well. After 2 h of incubation at 37°C and pH 6.8-7.3, non-adherent cells were gently removed and suspended in 900 µl human type AB serum (Merck KGaA) with 100 µl DMSO and cryopreserved at -80°C as a source of lymphocytes. The adherent monocyte-enriched cells were cultured at 37°C in 5% CO₂ incubator in AIM-V™ medium containing granulocyte-macrophage colony stimulating factor (50 ng/ml) and interleukin (IL)-4 (25 ng/ml) (Immunosensory GmbH) for 6 days to produce immature dendritic cells (iDCs). The iDCs were then matured to mature dendritic cells (mDCs) after incubation at 37°C in 5% CO₂, with tumor necrosis factor-α (50 ng/ml) and interferon (IFN)-γ (50 ng/ml) (Immunosensory GmbH) in AIM-V™ medium for 2 days. Subsequently, wells containing ~5x10⁶ mDCs were pulsed with 10 µg cancer cell-derived RNA. For phenotypic analysis of DCs, 5x10⁶ DCs were detached with 5 mM EDTA, washed in 2% FBS/PBS and incubated with fluorescence-conjugated monoclonal antibodies (1:50) at 4°C for 30 min. Following washing in 2% FBS/PBS twice, cells were analyzed using a CytoFLEX flow cytometer. To determine the phenotype of monocytes and DCs, anti-CD11c APC (1:50; cat. no. 21487116; Immunosensory GmbH), anti-CD14 APC (1:50; cat. no. 21620414; Immunosensory GmbH), anti-CD14 FITC (1:50; cat. no. 21620413; Immunosensory GmbH), anti-CD40 FITC (1:50, cat. no. 21270403; Immunosensory GmbH), anti-CD83 phycocerythrin (PE; 1:20; cat. no. 12-0839-42; Thermo Fisher Scientific, Inc.), anti-CD86 PE (1:20; cat. no. 12-0869-42; Thermo Fisher Scientific, Inc.) and anti-HLA-DR FITC (1:50; cat. no. 21278993; Immunosensory GmbH) monoclonal antibodies were used. To determine human leukocyte antigen-A2 (HLA-A2) expression, PBMCs from healthy donors were collected using the method described above and analyzed using anti-HLA-A2 APC antibody (1:50; cat. no. 17-9876-42; Immunosensory GmbH) and the CytoFLEX Flow cytometer.

Total effector lymphocytes and CD8+ T cell preparation. Cryopreserved lymphocytes were thawed and resuspended in RPMI medium Thermo Fisher Scientific, Inc.) supplemented with 5% human AB serum (Merck KGaA). The lymphocytes were activated by co-culture with RNA-pulsed mDCs at a ratio of 10:1 for 1 day. Subsequently, lymphocytes were cultured at 37°C in RPMI medium supplemented with 5% human AB serum, IL-2 (20 ng/ml), IL-7 (10 ng/ml) and IL-15 (20 ng/ml) (Immunosensory GmbH) for 9 days. The culture medium was replaced every other day.

Cytotoxic T cells were isolated using a CD8+ T cell Isolation kit (Miltenyi Biotec, Inc.) according to the manufacturer's protocol. In brief, 1x10⁷ lymphocytes were centrifuged at 300 x g for 10 min at room temperature and resuspended in 40 µl buffer containing PBS, 0.5% bovine serum albumin (Capricon Scientific) and 2 mM EDTA. The cell suspension was mixed and incubated with 10 µl of a CD8+ T cell biotin-antibody cocktail (Miltenyi Biotec, Inc.) for 5 min, followed by 20 µl of a CD8+ T cell micro-bead cocktail (Miltenyi Biotec, Inc.) for 10 min at room temperature. The cell mixture was then magnetically separated using a magnetic-activated cell sorting (MACS) column and MACS separator (Miltenyi Biotec, Inc.), and the flow-through enriched in CD8+ T cells were collected. To determine the phenotype of effector immune cells, anti-CD3 FITC (cat. no. 21850033; Immunosensory GmbH), anti-CD4 APC (cat. no. 21850046; Immunosensory GmbH), anti-CD8 APC (cat. no. 21620086; Immunosensory GmbH), anti-CD16 APC (cat. no. 21278166; Immunosensory GmbH) and anti-CD56 PE (BioLegend, Inc.) monoclonal antibodies were used. Phenotype markers of lymphocytes, including CD3, CD4, CD8, CD16 and CD56 were analyzed using a FACS caliber flow cytometer (BD Biosciences) using Flow Jo (Treestar) software version X.

IFN-γ measurement by ELISA. Amounts of IFN-γ secreted by CSC RNA-pulsed DC-activated T cells in comparison with naïve T cells was measured using an IFN-γ ELISA kit (cat. no. DIF50, R&D Systems, Ltd.) according to the manufacturer's protocol. Cytokine concentration was determined by measuring optical density using a microplate reader at 450/570 nm.

Tumor cell killing by effector T cells. BC target cells (T), either the whole culture population (BCA55-121-WP) or the enriched BCA55-121-CSCs, were plated into separate wells of 96-well plates (~3,000 cells/well) for 24 h for the assessment of immune cell killing activity. Subsequently, 50 µl Caspase-3/7 green reagent (Sartorius AG) at a 20 µM concentration was added to detect apoptosis. Total lymphocytes (E) from healthy donors with HLA matched to that of BCA55-121 cells (HLA-A2) were added as effectors and co-cultured with the tumor target cells (T) at effector to target (E:T) ratios of 5:1, 10:1 and 20:1 for 24 h. Cancer cells with apoptotic activity were detected using an IncuCyte® live-cell analysis system.

Statistical analysis. All data are presented as the mean ± standard deviation (SD). The data were tested for normal distribution by the Shapiro-Wilk test. The data from two groups were analyzed by paired Student’s t-test and from multiple groups by one-way repeated-measure analysis of variance (ANOVA) followed by Tukey’s post-hoc test using GraphPad Prism software version 7.04 (GraphPad Software, Inc.) or SigmaPlot 16.0 (Systat Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Characterization of the primary BC cell line BCA55-121. The tumor size measured 4.5x4x2 cm³, and was diagnosed as an invasive ductal carcinoma (moderately-differentiated) positive for estrogen receptor (>75%) and progesterone receptor (<10%) and negative for HER2/neu. Angiolympathic invasion was absent, however, one lymph node was positive for...
macrometastatic cancer cells. The cancer cells were visualized as cobblestone shaped under phase-contrast microscopy (data not shown). The primary cell line was positive for pan-keratin, confirming that the cells were of epithelial origin (18) and without stromal fibroblast contamination in the culture (Fig. 1A). The cell line also tested negative for fibroblast activation protein (FAP), and PD-L1 was expressed at a very low level (Fig. 1A). Chromosomal analysis revealed an aneuploid aberration of chromosome copies. BCA55-121 cells exhibited a higher proliferation rate compared with the MCF-7 cell line, but lower than that of MDA-MB-231 cells (Fig. 1A). Breast CSCs, defined as CD44+/CD24- cells, were separated from the BCA55-121-WP cells by fluorescence-activated cell sorting. These CSC markers were expressed in ~75.2±0.45% of the BCA55-121-WP population (Fig. 1B). CSCs were subsequently sorted to enrich the cells with this phenotype to
92.9±5.83% purity (Fig. 1B). The tumorigenic ability of the BCA55-121-CSCs were tested, and the results were compared with BCA55-121-WP cells. Soft agar colony formation assay, a 3D spheroid cell culture assay that measures cell proliferation in semi-solid matrices (11) was conducted. The assay selectively enriches cells that exhibit a malignant transformation, anchorage-independent proliferation and progenitor cell-like tumorigenic properties. Significantly greater proliferative and tumorigenic abilities (2-3 folds) of the BCA55-121-CSC population were indicated by colony count and colony size compared with unsorted BCA55-121-WP cells (Fig. 1C). The level of OCT4 was increased in BCA55-121-CSCs compared with the unsorted cells (Fig. 1D). NANOG expression did not change in BCA55-121-CSC compared with BCA55-121 WP, and the level of SOX2 was very low. These results confirmed the greater tumorigenic and stemness properties of the CSC-enriched population. In addition, the expression of PD-L1 was significantly increased in the CSC population of the CSC culture compared with the WP culture (Fig. 1E).

**Activation of PBMC-derived DCs and lymphocytes.** DC phenotype was analyzed on days 1 (monocytes), 6 (iDCs) and 9 (mDCs). Monocytes are the only cell type that expresses CD14 (19), and this was diminished during subsequent maturation and replaced by a DC marker (CD11c), a DC maturation marker (CD83), an antigen-presenting molecule (HLA-DR) and co-stimulatory molecules (CD40 and CD86; Fig. 2A) demonstrating DC maturation in vitro. The subsets of cells in the activated lymphocyte population following co-culture with DCs were analyzed by flow cytometry. The highest proportion of cytotoxic T lymphocytes in the total lymphocytes was observed after co-culture with RNA-pulsed DCs followed by CD4+ T cells (Fig. 2B). NK cell and NKT cell populations were also identified among the activated lymphocytes (Fig. 2B). In addition, a significantly increased number of IFN-γ-positive CD8+ T cells were observed on day 18 of the lymphocyte activation protocol (day 9 after co-culture with RNA-pulsed DC; Fig. 2C). For each of the three healthy donors, higher levels of secreted IFN-γ were present in the supernatants of activated T cells compared with the supernatants of naïve T cells (Fig. 2D).

**Cancer cell killing assay.** Total RNA from BCA55-121-CSC was loaded onto DCs, and the efficacy in activating effector
lymphocytes to kill cancer cells was measured using Caspase-3/7 reagents for apoptosis with the Live-cell imager. To prevent the killing of cancer cells by other immune cells, not effector CD8+ T cells, HLA-A2 matched lymphocytes and BCA55-121 cells were used. The efficacy of tumor cell killing between lymphocytes activated by BCA55-121-WP and CSC RNA-pulsed DCs was compared (Fig. 3). The killing activity in the CSC RNA-activated lymphocytes was greater compared with that of BCA55-121-WP or CSCs, and this was at either 10:1 or 20:1 E:T tumor cells with significance reached at 20:1 E:T ratio (Fig. 3). Green fluorescence, representing cells with activated Caspase-3/7 at different E:T ratios, is displayed in Fig. 4A. Although increasing apoptotic activity over time was observed in both experiments, a 10:1 ratio of total activated lymphocytes did not result in enhanced killing of CSC targets, although BCA55-121-WP cells were killed (Fig. 4B and C). Additionally, at a 20:1 ratio, more BCA55-121-WP cells were killed compared with CSCs at all time points (Fig. 4B and C). These results demonstrated that apoptotic resistance may be a property of CSCs. In addition, CD8+ effector T cells isolated from the CSC RNA-activated lymphocyte population revealed its superior proliferative and tumorigenic capability in an anchorage-independent 3D culture assay compared with BCA55-121-WP. This ability was associated with high expression of stem cell-associated proteins, confirming the stem cell properties of a new in-house BC cell line, BCA55-121-CSC. In the present study, higher expression of PD-L1 was observed in the CSC population of the CSC culture compared with the CSC population of the WP culture. These results were supported by previous studies, in which PD-L1 expression was positively associated with the expression of stemness markers (20,21), and supported the notion that BCA55-121-CSC cultures possessed CSC properties. In the present study, CSC RNA could be presented as tumor antigens by DCs and activated T cells in the whole T cell population and enriched CD8+ T cells, to stimulate an enhanced ability to kill cancer cells superior to that obtained using RNA from the total BCA55-121 cell population. BCA55-121-CSCs were more resistant to activated effector T cells compared with the whole BCA55-121 cell population. In the current study, total lymphocytes yielded an improved killing effect on both BCA55-121-WP and BCA55-121-CSC populations compared with effector CD8+ T cells as the total lymphocyte population contains CD4+, NK and NKT cells, which may have an effect on cancer cell killing.

Tumor-associated antigens (TAAs), in the form of peptides, protein lysates or total RNA, were capable of priming DCs for effector lymphocyte activation (22,23). Peptide antigens can be loaded directly onto MHC molecules; however, it is mandatory to match the immunogenic epitopes relevant to a particular cancer cell with the complementary specific HLA haplotype (15). The single best immunogenic TAA epitope in BC is yet to be defined, cancer-derived RNA has been used to present a broad range of TAA epitopes on various MHC haplotypes present on DCs (24,25). The RNA-based antigen approach has been most commonly used in clinical studies, offering HLA class I and II cross-presentation and in turn inducing humoral and cellular immune responses in CD4+ and CD8+ T cells (26-28). The present study compared

Discussion

The present study explored the potential of DC-primed T cells to alleviate treatment-refractory BC. CSCs were selected as a major target to alleviate cancer recurrence and aggressiveness. CD44+/CD24− was used as a CSC marker, and subsequent analyses of this subpopulation revealed its superior proliferative and tumorigenic capability in an anchorage-independent

Figure 3. Tumor cell apoptosis caused by effector T cells activated by BCA55-121-WP-RNA-pulsed DCs and those activated by BCA55-121-CSC-RNA-pulsed DCs. Cancer cell apoptosis was assessed by an immune cell killing assay using the IncuCyte® live cell analysis system. Time-dependent cancer cell apoptotic count induced by total lymphocytes against (A and B) BCA55-121-WP and BCA55-121-CSC compared with the apoptotic cell count of each condition at 0 h. The y-axis represents the numbers of apoptotic cells compared with those in the control group at the starting point of each treatment condition. The data are from triplicate wells of one experiment. *P<0.05 vs. T cells from the unpulsed DCs. CSC, cancer stem cell; DCs, dendritic cells; WP, whole population.
the cancer cell killing ability of T cells activated by DCs pulsed with total RNA with those activated by protein lysate-pulsed DCs and demonstrated that the ability to induce cancer cell apoptosis was greater in the former (data not shown). Moreover, the use of RNA avoids the effects of the immunosuppressive factors present in the tumor protein lysate; therefore, pulsing DCs with RNA may result in improved function (24,25). Taken together, this evidence supports the selection of total RNA as the antigen source in the present study. The present study demonstrated that CSC-RNA-pulsed DCs induced effector lymphocytes to kill both BCA55-121-WP and BCA55-121-CSCs, and the killing activity was superior compared with that of DCs that received RNA from whole cancer cells, which contained a mixture of both non-CSCs and CSCs. These results emphasized the potential of DC-based protocols using CSC RNA to prime DCs for eradication of tumor cells via tumor antigen-specific effector T cells.

In the present study, the T cell population activated by co-culture with RNA-primed DCs consisted of mainly cytotoxic and helper T cells together with some NKT and NK cells. These activated T cells produced high levels of IFN-γ, which is characteristic of effector T cells (29). These findings were consistent with
another report that confirmed the potential of *ex vivo* activation of effector T cells with an enhanced specificity for cancer antigens appropriate for use in adoptive transfer (30). In the present study, cancer cell killing by the effector T cells generated with CSC RNA-pulsed DCs was significantly greater compared with T cells activated with unpulsed DCs, and the effect was dose-dependent. Substantial killing was observed in cultures of unpulsed DC-activated T cells, which may be due to two main factors. The first is the presence of non-antigen specific cancer killing cells in the total lymphocyte population, comprising NK and NKT cells, which are also activated by DCs. In the present study, non-specific killing by other immune cells was addressed by isolating CD8+ T cells from the activated total lymphocyte population. The tumor-killing effect of the activated CD8+ T cells demonstrated a greater specificity of killing, potentially by antigen-dependent cytotoxic T cells, since little or no killing was observed among unpulsed-DC-activated CTLs. The efficacy of tumor killing between lymphocytes activated by whole culture RNA-pulsed DCs and CSC RNA-pulsed DCs was further compared. The results of the present study revealed superior tumor killing activity with the CSC RNA-activated cells, especially at 20:1 and 10:1 E:T ratios. Inferior apoptotic activity was observed towards BCA55-121-CSC target cells. The second potential mechanism of killing in unpulsed cultures maybe the mismatch of HLA molecules between effector cells derived from healthy donors and the target cancer cells. HLA-A2 matched donors were used in the present study as the BCA55-121 cancer cell line is HLA-A2 positive; however, residual HLA haplotype mismatch may have stimulated a small amount of non-specific killing and prevented optimal antigen presentation and effector cell activation leading to lower specific cytotoxicity in RNA-pulsed cultures. However, in the clinical application of DC-based vaccines, autologous DCs are activated by autologous tumor antigens and thus eliminate this confounder (14,16). The limitation of this study was the lack of investigation of HLA class I expression in DC. In addition, using only one donor was a limitation of the experiment presented in this study.

The present study revealed that CSCs were more resistant compared with the whole cancer cell population to effector T cells. This may be explained by the finding that the CSC population in CSC cultures expressed high levels of PD-L1 (20), which may induce apoptosis of effector T cells (31). These *in vitro* findings need to be investigated in an *ex vivo* system and in clinical trials for the development of DC-based activation of T cells against breast CSCs. A combination of drugs targeting CSCs and activated effector T cells may be a potential approach for resolving the issue of the resistant CSC population. This treatment needs to be developed alone or in conjunction with other treatments to optimize antitumor immune responses and overcome the relatively immunosuppressive stage, during which DCs in the tumor and the surrounding microenvironment develop tolerance (32,33). Personalized cancer therapy may be achieved by the activation of patient-derived DCs by using autologous tumor antigens from surgical tissue-derived primary cell culture. Several studies performed using the personalized DC-based vaccine have confirmed potent anti-tumor immunity activity mediated by a broad range of TAAs relevant to each patient (34-36). This approach has the potential to improve the efficacy of treatment and quality of life for patients with BC.

Acknowledgments

Not applicable.

Funding

This research project was supported by the Faculty of Medicine, Siriraj Hospital, Mahidol University (grant no. R015933006) and by the Thailand Science Research and Innovation (grant no. RSA6280091), Ministry of Higher Education, Science, Research and Innovation, Thailand awarded to CT.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

NS, NJ, PJ and ST performed the experiments and acquired the data. CT conceived and designed the study, acquired, analyzed and interpreted the data. TC, PY and PT analyzed the data. MW and PO collected the breast cancer tissue samples and verified clinicopathological data. NS, NJ and CT drafted the article. CT revised the manuscript for important intellectual content. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all individual participants prior to enrollment in the study. The present study was approved by the Siriraj Institutional Review Board (approval nos. Si520/2010 and Si321/2016).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandonia R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. *JAMA Oncol* 3: 524-548, 2017.
2. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS and Goldhirsch A: Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. *J Clin Oncol* 34: 927-935, 2016.
3. Gerber B, Freund M and Reimer T: Recurrent breast cancer: Treatment strategies for maintaining and prolonging good quality of life. *Dtsch Arztebl Int* 107: 85-91, 2010.
4. Dawood S, Austin L and Cristofanilli M: Cancer stem cells: Implications for cancer therapy. *Oncology (Williston Park)* 28: 1101-1107, 1110, 2014.
5. Palucka K and Banchereau J: Dendritic-cell-based therapeutic cancer vaccines. *Immunity* 39: 38-48, 2013.
6. Abdullah LN and Chow EK: Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2: 3, 2013.
7. Carrasco E, Alvarez PJ, Prados J, Melguizo C, Rama AR, Aránega A and Rodríguez-Serrano F: Cancer stem cells and their implication in breast cancer. Eur J Clin Invest 44: 678-687, 2014.
8. Dey P, Rathod M and De A: Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press) 11: 115-135, 2019.
9. Islam F, Gopalan V, Smith RA and Lam AK: Translational potential of cancer stem cells: A review of the detection of stem cell markers and their roles in cancer recurrence and cancer treatment. Exp Cell Res 335: 135-147, 2015.
10. Britton KM, Kirby JA, Lennard TW and Meeson AP: Cancer stem cells and side population cells in breast cancer and metastasis. Cancers (Basel) 3: 2106-2130, 2011.
11. Akrak N, Andersson D, Bom E, Gregersson P, Ståhliborg A and Landberg G: Identification of distinct breast cancer stem cell populations based on single-cell analyses of functionally enriched stem and progenitor pools. Stem Cell Reports 6: 121-136, 2016.
12. Shao J, Fan W, Ma B and Wu Y: Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Mol Med Rep 14: 4991-4998, 2016.
13. Gelao L, Criscitiello C, Esposito A, De Laurentis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A and Curigliano G: Dendritic cell-based vaccines: Clinical applications in breast cancer. Immunotherapy 6: 349-360, 2014.
14. Constantino J, Gomes C, Falcão A, Cruz MT and Neves BM: Antitumor dendritic cell-based vaccines: Lessons from 20 years of clinical trials and future perspectives. Transl Res 168: 74-95, 2016.
15. Sabudo RL, Balan S and Bhardwaj N: Dendritic cell-based immunotherapy. Cell Res 27: 74-95, 2017.
16. Anguille S, Smits EL, Lion E, van Tendeloo VF and Curigliano G: Identification of dozens of breast cancer stem cell markers: Stem cell markers and their roles in breast cancer recurrence and cancer treatment. Exp Cell Res 335: 135-147, 2015.
17. Britton KM, Kirby JA, Lennard TW and Meeson AP: Cancer stem cells and side population cells in breast cancer and metastasis. Cancers (Basel) 3: 2106-2130, 2011.
18. Andergassen U, Vogl A, Mumm JM, Kühl AC, Hutter S, Rack B, Friese K and Jeschke U: Immunocytochemical characterization of disseminated tumour cells from bone marrow of breast cancer patients. Anticancer Res 36: 3217-3222, 2016.
19. Zarif JC, Hernandez JR, Verdone JE, Campbell SP, Drake CG and Pienta KJ: A phased strategy to differentiate human CD14+ monocytes into classically and alternatively activated macrophages and dendritic cells. Biotechniques 61: 33-41, 2016.
20. Darvin P, Saisidharan Nair V and El-Kord E: PD-L1 Expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. J Oncol 2019: 3958908, 2019.
21. Gao L, Guo Q, Li X, Yang X, Ni H, Wang T, Zhao Q, Liu H, Xing Y, Xi T and Zheng L: MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine 41: 395-407, 2019.
22. Yin T, Shi P, Gao S, Shen Q and Wang C: Dendritic cells loaded with breast cancer stem cells (CSCs) lytes induce anti-tumor immune killing effect in vivo. PLoS One 9: e114581, 2014.
23. Xie BH, Yang JY, Li HP, Zhang B, Chen W, Zhou B, Peng BG, Liang L and He Q: Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo. Clin Transl Oncol 16: 753-760, 2014.
24. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
25. Criscitiello C: Tumor-associated antigens in breast cancer. Breast Care (Basel) 7: 262-266, 2012.
26. Garg NK, Dwivedi P, Prabha P and Tyagi RK: RNA pulsed dendritic cells: An approach for cancer immunotherapy. Vaccine 31: 1141-1156, 2013.
27. McNamara MA, Nair SK and Holl EK: RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015: 794528, 2015.
28. Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39: 1-10, 2013.
29. Bhat P, Leggatt G, Waterhouse N and Frazer IH: Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis 8: e2836, 2017.
30. Nguyen ST, Nguyen HL, Pham VQ, Nguyen GT, Tran CD, Phan NK and Pham PV: Targeting specificity of dendritic cells on breast cancer stem cells: In vitro and in vivo evaluations. Onco Targets Ther 8: 323-334, 2015.
31. Paradis B: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
32. Duraiswamy J, Kaluza KM, Freeman GJ and Coukos G: Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73: 3591-3603, 2013.
33. Zong J, Keskinov AA, Shurin GV and Shurin MR: Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother 65: 821-833, 2016.
34. Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, Mizuno Y, Yamaoka N, Yuzawa M, Kobayashi T, Ito K and Koziumi T: Dendritic cell-based adjuvant vaccination targeting Wilms’ tumor 1 in patients with advanced colorectal cancer. Vaccines (Basel) 3: 1004-1018, 2015.
35. Chen Y, Yao K, Wang B, Qing J and Liu G: Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A). Cell Mol Immunol 5: 365-372, 2008.
36. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenh G, van Rees B, et al: Immunogenicity of dendritic cells pulsed with MAGE3, survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 62: 1381-1392, 2013.